61 publications
Name | Date | Type | Actions |
---|---|---|---|
Strong growth in Revenues in the 3rd quarter Vétoquinol recorded strong growth in the 3rd quarter of 2009, despite an unfavourable exchange rate effect. The strength in sales was due to a combination of the contribution of acquisitions in Italy and India and sustained organic growth. |
14/10/2009 | Public releases | |
VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success. |
14/01/2010 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
20/04/2023 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
16/10/2019 | Public releases |